Cadila Pharma Unveils Herbal Products In Kerala

Kochi, September 16: | Updated: Sep 17 2003, 05:30am hrs
Pharma major Cadila Pharmaceuticals Ltd, which recently ventured into the herbal segment, has moved South by launching its products in Kerala on Monday. The company was planning to come out with four more products that include a prickly heat powder, an aphrodisiac, hair oil and a winter care cream.

Kerala, with background of being well-acquainted with auyrveda, was considered fit to be the launching pad for this range of eight products based on ayurvedic formulations, according to company vice-president Krishna Mohan.

The products already launched in North India and states like Maharashtra, Gujarat, Bihar and Jharkand were well-received, he said, adding that the company had set a business plan of Rs 200 crore.

The company was taking the franchisee route for marketing its products throughout the country and will now move to the East.

It had already begun exporting the products to Russia and was in talks with the authorities in the US and European Union States.

The clearance of the Belgian authorities was accepted any time, he added.

The company had applied for patent right for a few drugs and was in the process of applying for a few more. The Ahmedabad-based company had set up a full-fledged phytochemistry R&D facility over a decade ago with an investment of Rs 10 crore, foreseeing the emerging trend of worldwide demand for alternative medicines.

The company, a leader in ethical medicines, felt that it needed to cash in on the countrys strength and was planning to emerge stronger in this segment, Dr Krishna Mohan said.

It had a team of auyrveda consultants, botanists and formulation scientists for developing the products, which included a pain reliever ointment, a cough syrup, a mouthwash and an anti-septic cream.

It also had a range of veterinary drugs based on auryuvedic formulations. As the drugs were based on the pharmacopoeia and medical standards of different countries, he felt that the company will not face problems in exporting the drugs.